Table 2.

Incidence of grade ≥ 2 adverse events in patients under different regimens

Adverse event	Oxaliplatin	Paclitaxel	Irinotecan	Cetuximab/panitumumab	Anthracycline + cyclophosphamide	Vincristine	Docetaxel	Carboplatin	Gemcitabine	Nivolumab/pembrolizumab
	N = 726	N = 1259	N = 529	N = 221	N = 181	N = 113	N = 172	N = 188	N = 547	N = 568
Constipation	2.75%	3.57%	2.08%	0.04%	9.39%	15.04%	7.56%	3.72%	3.47%	1.41%
Nausea	2.62%	0.48%	3.78%	0.01%	1.66%	0.00%	0.58%	0.00%	0.91%	0.18%
Diarrhea	0.55%	0.56%	0.57%	0.00%	0.00%	0.00%	0.00%	0.00%	0.18%	0.53%
Vomiting	0.41%	0.32%	0.57%	0.00%	0.55%	0.00%	0.00%	0.00%	0.37%	0.35%
Oral mucositis	0.55%	0.08%	1.13%	0.01%	1.66%	0.88%	2.33%	0.00%	0.00%	0.00%
Malaise	1.52%	2.07%	1.89%	0.01%	2.76%	4.42%	2.91%	4.26%	4.20%	0.53%
Pain	0.00%	1.03%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.73%	0.00%
Edema limbs	0.00%	0.08%	0.00%	0.00%	0.00%	0.00%	1.16%	0.00%	0.00%	0.88%
Nail fever	0.69%	0.00%	0.76%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Anorexia	3.72%	2.94%	3.78%	0.00%	0.55%	0.00%	7.56%	2.66%	3.29%	2.11%
Arthralgia	0.00%	0.64%	0.00%	0.00%	0.00%	0.00%	0.00%	0.53%	0.73%	0.00%
Muscle pain	0.00%	0.56%	0.00%	0.00%	0.00%	0.00%	0.00%	0.53%	0.91%	0.00%
Tumor pain	0.41%	0.87%	0.57%	0.00%	0.00%	0.00%	0.58%	0.00%	0.37%	0.70%
Peripheral neuropathy	3.17%	3.65%	3.78%	0.03%	6.08%	9.73%	0.58%	0.00%	3.29%	1.23%
Taste disorder	0.96%	0.87%	0.95%	0.00%	0.55%	0.00%	2.33%	0.00%	3.66%	0.53%
Hand-foot syndrome	0.14%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Alopecia	0.14%	5.00%	0.95%	0.00%	0.55%	0.00%	4.07%	2.66%	2.01%	1.06%
Pruritus	0.00%	0.00%	0.19%	0.00%	0.00%	0.00%	0.58%	0.00%	0.00%	0.00%
Dry skin	0.41%	0.00%	0.95%	0.00%	0.00%	0.00%	1.16%	0.00%	0.00%	0.18%
Acneiform eruption	0.14%	0.08%	0.19%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%